Structure Therapeutics Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 17, 2023. Amounts below are U.S. dollars unless noted. The company is a clinical-stage biopharmaceutical developer and has not generated product revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue; the filing reports no product sales to date. | |||
| Research and development expense | $17.5 million | $9.2 million | $50.1 million | $27.8 million |
| General and administrative expense | $8.6 million | $3.5 million | $21.7 million | $11.8 million |
| Total operating expenses | $26.1 million | $12.7 million | $71.8 million | $39.6 million |
| Net loss | $23.9 million | $12.4 million | $65.1 million | $39.4 million |
| Net loss per ordinary share, basic and diluted | $0.21 | $1.27 | $0.65 | $4.34 |
| Interest and other income, net | $2.7 million | $0.3 million | $7.2 million | $0.4 million |
Margins are not meaningful because the company reported no product revenue. R&D expense growth principally reflected advancement of the GLP-1 receptor program, clinical activity and increased personnel costs. G&A growth reflected professional and employee expenses, including costs of operating as a public company. Higher interest income reflected larger investment balances and higher interest rates.
- Liquidity at September 30: Cash and cash equivalents were $50.6 million and short-term investments were $154.8 million, totaling $205.4 million. Current assets were $210.0 million; total assets were $216.4 million.
- Cash flows, nine months: Operating activities used $57.8 million; investing activities used $87.6 million, mainly net purchases of short-term investments; financing activities provided $169.9 million, principally IPO proceeds. Cash and cash equivalents increased $24.5 million to $50.6 million.
- Debt and obligations: The filing reports no outstanding borrowings. Operating lease liabilities totaled $3.9 million, including $0.8 million current; undiscounted lease payments were $4.4 million. The company reported $182.1 million of accumulated deficit.
Material changes versus comparable periods
- Q3 R&D expense rose 91% and G&A expense rose 144% year over year; nine-month R&D and G&A increased 80% and 84%, respectively. Nine-month net loss grew to $65.1 million from $39.4 million.
- Per-share loss was lower than in 2022 despite a larger net loss, largely reflecting a substantially higher weighted-average share count after the February 2023 IPO and conversion of preferred shares.
- The February 2023 IPO generated approximately $166.7 million net proceeds. All outstanding preferred shares converted into ordinary shares at the IPO.
- A private placement agreed September 29 closed October 3, 2023, issuing 21.6 million ordinary shares and 2.4 million non-voting ordinary shares for $300.0 million gross proceeds, before fees and expenses. Placement agents are entitled to a combined fee of 6.0% of gross proceeds plus certain expense reimbursement.
Outlook, development, risks and unusual items
- Cash runway: Management estimated that cash, cash equivalents and short-term investments at quarter-end, together with net proceeds from the private placement, would fund projected operations through at least 2026. The notes separately state that quarter-end resources alone were expected to cover at least 12 months from issuance of the financial statements. Both estimates depend on assumptions and spending may exceed expectations.
- GSBR-1290: The company reported September topline Phase 1b data showing general tolerability, no adverse-event-related discontinuations, and weight loss of up to 4.9% placebo-adjusted over 28 days. Phase 2a diabetes-cohort data and a Japanese ethno-bridging study were expected in December 2023. A data-collection omission at one site left week-12 weight measurements missing for 24 of 40 participants in the obesity cohort; replacement enrollment delayed expected topline results to the first half of 2024. Tablet formulation-bridging results were expected in Q2 2024, with global Phase 2b studies for diabetes and obesity planned to start in the second half of 2024.
- Other pipeline and safety: GSBR-1290 and ANPA-0073 were in early clinical development; other programs were preclinical or in discovery. In a 13-week non-human-primate toxicology study, low-to-moderate liver necrosis was observed across dosing groups, including controls; management said it was not attributed to GSBR-1290 but cautioned the FDA could disagree. Clinical-trial outcomes remain uncertain.
- Capital needs: Management expects significant and increasing losses and R&D spending, and says substantial additional capital will be needed over time. Financing may dilute shareholders or require restrictive terms or licensing of valuable rights.
- Financial reporting controls: Disclosure controls were not effective as of September 30 due to material weaknesses involving staffing and control environment, segregation of financial duties, and IT general controls. Management said the weaknesses had not caused material misstatements and remediation was underway; effectiveness had not yet been demonstrated.
- Other risks and contingencies: The company depends on third parties for clinical trials and manufacturing; it identified WuXi STA as its single-source supplier for active ingredients and drug product. It highlighted clinical, regulatory, IP, competition, China-related, macroeconomic and supply-chain risks. The filing reported no known legal matter expected to have a material adverse effect and no material probable or reasonably possible indemnification claims.
- Subsequent collaboration: In November 2023, a subsidiary entered a discovery collaboration with Schrödinger. Potential obligations include up to $89.0 million in development, regulatory and commercialization milestones, plus low-single-digit royalties if products are commercialized.
Important facts for investors to verify
- Whether the replacement enrollment resolves the Phase 2a obesity-cohort data omission and whether upcoming GSBR-1290 results support the stated development schedule.
- How the FDA views the liver findings in the non-human-primate study and the product’s safety as trials progress.
- Actual net proceeds from the October private placement after fees, and the resulting share count and potential dilution.
- Whether spending, trial expansion or other changes alter the stated runway through at least 2026.
- Progress and tested effectiveness of remediation for the material weaknesses in internal controls.
- Manufacturing continuity and the financial and operational terms of the Schrödinger collaborations.